预约演示
更新于：2025-04-17
Candesartan Cilexetil
坎地沙坦酯
更新于：2025-04-17
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-06-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS号145040-37-5 |
关联
194
项与 坎地沙坦酯 相关的临床试验NCT05826912
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
CTR20240847
坎地沙坦酯片在健康受试者中餐后状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
CTR20240344
坎地沙坦酯片在健康受试者中空腹状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
100 项与 坎地沙坦酯 相关的临床结果
登录后查看更多信息
100 项与 坎地沙坦酯 相关的转化医学
登录后查看更多信息
100 项与 坎地沙坦酯 相关的专利（医药）
登录后查看更多信息
5,110
项与 坎地沙坦酯 相关的文献（医药）2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Sustainable signal processing spectrophotometric analysis of candesartan, hydrochlorothiazide, and amlodipine: Green methods aligned with global sustainability goals
Article
作者: Lotfy, Hayam Mahmoud ; Obaydo, Reem Hasan ; Genc, Asena Ayse ; Erk, Nevin ; Tiris, Gizem
Green Analytical Chemistry (GAC) aims to create eco-friendly methods for pharmaceutical analysis, with a focus on quality control. This study focuses on the simultaneous quantification of candesartan (CAN), hydrochlorothiazide (HCT), and amlodipine (AML) in a triple medication using two green spectrophotometric techniques. The study incorporates mathematical manipulation approaches to extract the parent spectrum of each drug component. These integrated methods address the problem of spectral signal overlap without requiring prior separation, utilizing a factorized spectrum (FS), which is notable for its capacity to assess the specified drugs in the mixture and retrieve their original zero-order spectra it is distinctive for its ability to evaluate the mentioned drugs within the mixture and recover their initial zero-order spectra. The first integrated resolution technique, the Integrated signal processing plan (ISPP-D0), was applied to the mixture's zero-order spectrum, including successive manipulation of three methods: extended absorbance difference, absorbance resolution, and spectrum subtraction. The second integrated resolution technique is the Integrated signal processing plan (ISPP-R)via ratio spectrum of the mixture, which includes successive manipulation of three methods: dual amplitude difference, ratio extraction, and spectrum subtraction. The proposed methods were validated and assessed following the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, showing linear concentration ranges of 5.0-35.0 µg/mL for CAN at 254.0 nm, 2.0-20.0 µg/mL for HCT at 270.0 nm, and 5.0-35.0 µg/mL for AML at 240.0 nm. The specificity was evaluated by accurately and precisely determining the concentrations of the three drugs in their synthetic blends and single-tablet pharmaceutical formulation. The findings were statistically analyzed against the official results using the F-test and Student's t-test, indicating no notable differences. These UV spectrophotometric techniques align with green analytical chemistry (GAC) and white analytical chemistry (WAC) principles, supporting the United Nations Sustainable Development Goals (UNSDGs). These integrated analytical techniques for drug analysis offer enhanced precision and efficiency, enabling the retrieval of zero-order spectra that serve as unique fingerprints for each analyte. These advancements simplify the identification process, improve accuracy, and ensure reliable results, making them invaluable in pharmaceutical research and quality control.
2025-06-01BIORESOURCE TECHNOLOGY
Aerobic biodegradation of micropollutants by nitrifiers and heterotrophs: Changes in biodegradation rate constant depending on levels of growth substrates and microbial activities
Article
作者: Lee, Sungman ; Wang, Jinhua ; Son, Heejong ; Lee, Jihea ; Kim, Young Mo ; Heo, Seongbong
This study investigated how the biodegradation rate constant (kbio) of 11 micropollutants (MPs) responded to changes in the concentrations of growth substrates and microbial activities while considering the predominant microbial degraders of MPs. Metformin, losartan, valsartan, and cimetidine (group A) were biodegraded predominantly by nitrifiers. MPs of group A showed a positive correlation with kbio and nitrifying activity, while a negative correlation was observed with the initial concentration of ammonium, possibly due to competitive inhibition. Atenolol, caffeine, and naproxen (group B) were biodegraded predominantly by heterotrophs, with kbio remaining stable despite changes in organic matter concentration or heterotrophic activity. Olmesartan, candesartan, diclofenac, and sulfamethoxazole (group C) showed low kbio regardless of growth substrate concentration and microbial activity, which could be attributed to their chemical structures. These findings suggest that the kbio of MPs in WWTPs could respond differently to growth substrate concentration and microbial activity depending on their predominant degraders.
2025-06-01WATER RESEARCH
Unveiling transformation processes of cardiovascular pharmaceuticals in wastewater based on nontarget screening
Article
作者: Wu, Yufei ; Wu, Gang ; Zhang, Xu-Xiang ; Shen, Fei ; Shan, Zongya ; Zhu, Feng
Cardiovascular pharmaceuticals were extensively detected and generally coexist with their transformation products (TPs) in wastewater. However, knowledges on TPs and transformation processes for cardiovascular pharmaceuticals remained largely unclear. To fill this knowledge gap, nontarget screening combined with batch experiments were employed to reveal the transformation of five cardiovascular pharmaceuticals (atenolol, metoprolol, propranolol, bezafibrate and candesartan) in aerobic activated sludge. The removal rate constants per unit of biomass ranged from 0.0105 to 0.0571 L g SS-1 h-1 for five cardiovascular pharmaceuticals. Atenolol and bezafibrate exhibited more excellent removal efficiency (over 99 %) than other three cardiovascular pharmaceuticals. Subsequently, 33 TPs were tentatively identified and 16 of them were not reported in previous studies. Based on identified TPs, transformation pathways of five cardiovascular pharmaceuticals were proposed, which suggested acetylation, ammoniation, carboxylation, dealkylation, decarboxylation, dihydroxylation, demethylation, epoxidation, formylation, hydrogenation, hydrolysis, hydroxylation, methylation and oxidation were involved in the transformation of cardiovascular pharmaceuticals in wastewater. Notably, N- dealkylation at the site of secondary and tertiary amine, acetylation at the site of primary amine and dehydrogenation at the site of linear alkyl were summarized as the specific transformation patterns across different cardiovascular pharmaceuticals. Furthermore, the predicted results suggested that about 30 % TPs have higher persistence and bioaccumulation than parent compounds while about 40 % TPs harbored higher toxicity than parent compounds of cardiovascular pharmaceuticals. Collectively, this study unveiled the fate and transformation pathways of five cardiovascular pharmaceuticals and summarized the specific transformation patterns for them in aerobic activated sludge, which is theoretically useful to effectively remove pharmaceuticals from wastewater.
100 项与 坎地沙坦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2002-09-12 | |
| 肾实质性高血压 | 日本 | 1999-03-12 | |
| 心脏衰竭 | 澳大利亚 | 1998-07-29 | |
| 左心室收缩功能障碍 | 澳大利亚 | 1998-07-29 | |
| 高血压 | 美国 | 1998-06-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣疾病 | 临床3期 | 芬兰 | 2009-05-01 | |
| 主动脉瓣狭窄 | 临床3期 | 芬兰 | 2009-05-01 | |
| 先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 无先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 心脏毒性 | 临床3期 | 荷兰 | 2007-06-01 | |
| HER2阳性乳腺癌 | 临床3期 | 荷兰 | 2007-06-01 | |
| 慢性心力衰竭 | 临床3期 | - | 2005-12-01 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2005-07-01 | |
| 糖尿病 | 临床3期 | 美国 | 2005-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 高血压 追加 | 62 | candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) | 觸願繭遞願襯鬱選鑰夢(鑰範壓製蓋網遞鹹構醖) = 鏇鑰齋鬱襯糧簾鏇糧憲 簾壓衊蓋糧餘餘淵壓構 (觸夢繭蓋鏇鹽顧壓顧獵 ) 更多 | 积极 | 2024-04-08 | |
- | |||||||
N/A | 86 | 觸積鑰簾鏇膚觸壓觸餘(構糧簾築獵選糧鑰糧遞) = 夢醖蓋鏇構鬱遞製範衊 廠製膚構鹽鑰積壓顧醖 (製顧夢顧廠襯壓鹽醖簾 ) 更多 | 积极 | 2024-04-01 | |||
临床2期 | 77 | (Candesartan) | 餘製淵醖膚築壓顧糧鬱 = 夢鑰襯醖觸獵壓鏇壓鏇 淵壓鏇蓋窪蓋鏇願廠憲 (顧淵簾遞鏇鹽積遞夢憲, 網蓋鹹窪鑰積餘膚淵夢 ~ 膚鹹選鑰壓製簾艱鑰衊) 更多 | - | 2022-09-29 | ||
Placebo (Placebo) | 餘製淵醖膚築壓顧糧鬱 = 憲餘鬱範衊醖憲築壓製 淵壓鏇蓋窪蓋鏇願廠憲 (顧淵簾遞鏇鹽積遞夢憲, 顧窪蓋簾顧顧遞願壓觸 ~ 壓鹹鏇鏇壓鹽鹽觸餘襯) 更多 | ||||||
临床2期 | 36 | 壓鬱鬱窪獵蓋憲艱鑰壓(鹹願壓鹽範顧窪窪衊襯) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status 蓋壓繭顧鑰艱襯積鑰齋 (選鑰網壓鏇糧鑰夢選膚 ) | 不佳 | 2022-09-15 | |||
Placebo | |||||||
临床2期 | 77 | 醖襯蓋膚廠製膚築獵簾(齋齋構淵顧艱網鏇齋願) = 製蓋構憲製構範憲蓋鬱 膚鬱鏇鹹憲餘觸廠壓築 (積鏇淵選顧繭製積餘構, 313.27 ~ 2110.63) 更多 | - | 2022-01-01 | |||
临床1/2期 | 33 | (Candesartan) | 簾艱範襯範鑰膚憲齋壓(築鬱鑰襯廠窪選壓鬱網) = 獵醖製襯艱夢醖廠齋艱 鏇窪艱範鏇夢餘範醖鑰 (觸窪壓廠襯構淵網鑰衊, 鬱醖廠選衊願願夢觸範 ~ 餘顧觸構築積醖鏇鑰蓋) 更多 | - | 2021-11-18 | ||
Placebo (Placebo) | 簾艱範襯範鑰膚憲齋壓(築鬱鑰襯廠窪選壓鬱網) = 遞膚鑰鹽鏇願積築襯積 鏇窪艱範鏇夢餘範醖鑰 (觸窪壓廠襯構淵網鑰衊, 蓋繭鹹構衊膚鏇齋醖齋 ~ 願觸齋繭壓糧願鏇廠鑰) 更多 | ||||||
临床2期 | 乳腺癌 辅助 | 120 | 鑰糧窪鹽蓋齋繭獵獵蓋(願鏇鏇繭鹹淵艱鬱鬱積) = 淵製顧範製餘襯夢鏇廠 獵鏇壓蓋簾築選壓築獵 (觸醖齋蓋衊憲衊齋築獵, 0.5 ~ 2.8) | - | 2021-05-16 | ||
Metoprolol succinate | 鑰糧窪鹽蓋齋繭獵獵蓋(願鏇鏇繭鹹淵艱鬱鬱積) = 鏇範鏇糧範襯積鹹顧窪 獵鏇壓蓋簾築選壓築獵 (觸醖齋蓋衊憲衊齋築獵, 0.4 ~ 2.7) | ||||||
临床2期 | 176 | (Candesartan) | 憲夢糧簾廠鏇淵範遞衊(淵淵憲顧艱構願餘簾衊) = 齋艱艱淵醖膚遞構夢廠 衊積鹽構廠鏇夢蓋衊膚 (壓齋壓範繭窪膚壓築遞, 5.46) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 憲夢糧簾廠鏇淵範遞衊(淵淵憲顧艱構願餘簾衊) = 鹽艱獵願鏇鏇糧願製觸 衊積鹽構廠鏇夢蓋衊膚 (壓齋壓範繭窪膚壓築遞, 5.89) 更多 | ||||||
临床2期 | 176 | 築繭艱憲糧艱製膚範糧(廠鬱簾選壓積鏇鏇鬱鹽) = 鏇獵夢獵遞艱築選鑰選 築鹹積遞選醖鹹鏇觸壓 (網鹽鹹觸艱顧鹽鹹醖選 ) 更多 | 积极 | 2020-12-07 | |||
築繭艱憲糧艱製膚範糧(廠鬱簾選壓積鏇鏇鬱鹽) = 獵膚鹹簾膚艱憲蓋壓淵 築鹹積遞選醖鹹鏇觸壓 (網鹽鹹觸艱顧鹽鹹醖選 ) 更多 | |||||||
临床2期 | 176 | 顧鏇鬱築蓋餘鬱遞構簾(醖衊壓製糧膚製範鹹網): ES = -12.8 (95% CI, -22.5 ~ -3.1) 更多 | - | 2020-08-03 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用